JP2013501791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501791A5 JP2013501791A5 JP2012524769A JP2012524769A JP2013501791A5 JP 2013501791 A5 JP2013501791 A5 JP 2013501791A5 JP 2012524769 A JP2012524769 A JP 2012524769A JP 2012524769 A JP2012524769 A JP 2012524769A JP 2013501791 A5 JP2013501791 A5 JP 2013501791A5
- Authority
- JP
- Japan
- Prior art keywords
- temozolomide
- paclitaxel
- brain metastasis
- combination
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004556 brain Anatomy 0.000 claims 9
- 206010027476 Metastases Diseases 0.000 claims 8
- 229930012538 Paclitaxel Natural products 0.000 claims 8
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 8
- 230000009401 metastasis Effects 0.000 claims 8
- 229960001592 paclitaxel Drugs 0.000 claims 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 8
- 229960004964 temozolomide Drugs 0.000 claims 8
- 238000001959 radiotherapy Methods 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 claims 3
- 229960001039 macitentan Drugs 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000002719 stereotactic radiosurgery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23268709P | 2009-08-10 | 2009-08-10 | |
| US61/232,687 | 2009-08-10 | ||
| PCT/US2010/044832 WO2011019630A2 (en) | 2009-08-10 | 2010-08-09 | Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501791A JP2013501791A (ja) | 2013-01-17 |
| JP2013501791A5 true JP2013501791A5 (OSRAM) | 2013-09-19 |
Family
ID=42938154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524769A Ceased JP2013501791A (ja) | 2009-08-10 | 2010-08-09 | エンドセリン受容体の阻害剤による星状細胞−腫瘍細胞の処置 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8999934B2 (OSRAM) |
| EP (1) | EP2464218B1 (OSRAM) |
| JP (1) | JP2013501791A (OSRAM) |
| KR (1) | KR20120088665A (OSRAM) |
| CN (1) | CN102510719B (OSRAM) |
| AU (1) | AU2010282744B2 (OSRAM) |
| BR (1) | BR112012003103A2 (OSRAM) |
| CA (1) | CA2770397A1 (OSRAM) |
| CL (1) | CL2012000333A1 (OSRAM) |
| DK (1) | DK2464218T3 (OSRAM) |
| EA (1) | EA023864B1 (OSRAM) |
| ES (1) | ES2543280T3 (OSRAM) |
| HR (1) | HRP20150890T1 (OSRAM) |
| HU (1) | HUE026005T2 (OSRAM) |
| IL (1) | IL217915A0 (OSRAM) |
| IN (1) | IN2012DN01261A (OSRAM) |
| MA (1) | MA33571B1 (OSRAM) |
| MX (1) | MX2012001562A (OSRAM) |
| NZ (1) | NZ598078A (OSRAM) |
| PL (1) | PL2464218T3 (OSRAM) |
| PT (1) | PT2464218E (OSRAM) |
| SG (1) | SG178828A1 (OSRAM) |
| SI (1) | SI2464218T1 (OSRAM) |
| TN (1) | TN2012000054A1 (OSRAM) |
| TW (1) | TWI483938B (OSRAM) |
| WO (1) | WO2011019630A2 (OSRAM) |
| ZA (1) | ZA201200980B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501461A1 (en) * | 2011-02-04 | 2019-03-22 | Actelion Pharmaceuticals Ltd | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
| AU2012273182A1 (en) | 2011-06-21 | 2014-01-16 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| AU2016229295B2 (en) * | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| SG10202008673WA (en) | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| MX2018001507A (es) | 2015-08-03 | 2018-09-18 | Enb Therapeutics Llc | Composiciones y metodos para tratar cánceres asociados con la activacion del etbr. |
| JP6996728B2 (ja) * | 2016-01-07 | 2022-01-17 | 学校法人自治医科大学 | グルコーストランスポーター１発現用アデノ随伴ウイルスベクター |
| JP2019511565A (ja) | 2016-02-08 | 2019-04-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | ツカレゾールまたはそのアナログを含む組成物 |
| WO2017209272A1 (ja) * | 2016-06-03 | 2017-12-07 | 国立大学法人東京大学 | がん転移阻害剤 |
| AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20240110997A (ko) | 2017-02-01 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| WO2018152340A1 (en) | 2017-02-15 | 2018-08-23 | The Regents Of The University Of California | Compositions and methods for activating nk cells |
| CN111886010A (zh) | 2018-01-12 | 2020-11-03 | Enb治疗公司 | 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 |
| EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE |
| CN109232546B (zh) | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| CN113874364B (zh) | 2019-05-22 | 2024-04-05 | 无锡智康弘义生物科技有限公司 | 一种嘧啶磺酰胺类化合物的晶型及其制备方法 |
| CN112062857B (zh) * | 2019-06-10 | 2024-08-09 | 鸿运华宁（杭州）生物医药有限公司 | Eta抗体与bnp的融合蛋白质，及其药物组合物和应用 |
| WO2021062027A1 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Thalamic input to orbitofrontal cortex drives brain-wide, frequency-dependent inhibition mediated by gaba and zona incerta |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053557A1 (en) | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| WO2007031933A2 (en) * | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| CN101939001B (zh) | 2008-02-20 | 2012-06-20 | 埃科特莱茵药品有限公司 | 用于治疗卵巢癌的含有紫杉醇的组合 |
| PH12013501461A1 (en) | 2011-02-04 | 2019-03-22 | Actelion Pharmaceuticals Ltd | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
-
2010
- 2010-08-09 EP EP10742690.0A patent/EP2464218B1/en not_active Not-in-force
- 2010-08-09 US US13/390,072 patent/US8999934B2/en not_active Expired - Fee Related
- 2010-08-09 PT PT107426900T patent/PT2464218E/pt unknown
- 2010-08-09 JP JP2012524769A patent/JP2013501791A/ja not_active Ceased
- 2010-08-09 BR BR112012003103A patent/BR112012003103A2/pt not_active IP Right Cessation
- 2010-08-09 DK DK10742690.0T patent/DK2464218T3/en active
- 2010-08-09 AU AU2010282744A patent/AU2010282744B2/en not_active Ceased
- 2010-08-09 HU HUE10742690A patent/HUE026005T2/en unknown
- 2010-08-09 IN IN1261DEN2012 patent/IN2012DN01261A/en unknown
- 2010-08-09 TW TW099126507A patent/TWI483938B/zh not_active IP Right Cessation
- 2010-08-09 NZ NZ598078A patent/NZ598078A/xx not_active IP Right Cessation
- 2010-08-09 WO PCT/US2010/044832 patent/WO2011019630A2/en not_active Ceased
- 2010-08-09 KR KR1020127006203A patent/KR20120088665A/ko not_active Ceased
- 2010-08-09 ES ES10742690.0T patent/ES2543280T3/es active Active
- 2010-08-09 MX MX2012001562A patent/MX2012001562A/es active IP Right Grant
- 2010-08-09 EA EA201270264A patent/EA023864B1/ru not_active IP Right Cessation
- 2010-08-09 HR HRP20150890TT patent/HRP20150890T1/hr unknown
- 2010-08-09 PL PL10742690T patent/PL2464218T3/pl unknown
- 2010-08-09 CA CA2770397A patent/CA2770397A1/en not_active Abandoned
- 2010-08-09 CN CN201080040990.1A patent/CN102510719B/zh not_active Expired - Fee Related
- 2010-08-09 SI SI201031003T patent/SI2464218T1/sl unknown
- 2010-08-09 SG SG2012009338A patent/SG178828A1/en unknown
-
2012
- 2012-02-02 IL IL217915A patent/IL217915A0/en unknown
- 2012-02-03 TN TNP2012000054A patent/TN2012000054A1/en unknown
- 2012-02-08 CL CL2012000333A patent/CL2012000333A1/es unknown
- 2012-02-09 ZA ZA2012/00980A patent/ZA201200980B/en unknown
- 2012-03-08 MA MA34671A patent/MA33571B1/fr unknown
-
2015
- 2015-03-06 US US14/640,662 patent/US20150352113A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| SI3600281T1 (sl) | Kombinirana terapija za zdravljenje ali preprečevanje tumorjev | |
| NZ706836A (en) | Methods of treating cancer | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
| NZ749217A (en) | Androgen receptor modulator and uses thereof | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| MY174018A (en) | Heterocyclic derivates | |
| DK3791896T3 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
| JP2015500225A5 (OSRAM) | ||
| CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| CA2908957C (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| JP2009506054A5 (OSRAM) | ||
| ZA201300762B (en) | Novel combination therapy for the treatment of cancer | |
| TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| JP2014504636A5 (OSRAM) | ||
| WO2016106357A8 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| WO2013157889A9 (ko) | 신규한 아미노피리딘 유도체의 암 예방 또는 치료 용도 | |
| WO2012158933A3 (en) | Macrocycllc therapeutic agents and methods of treatment | |
| PH12014501537A1 (en) | Therapeutic use of imidazopyridine derivatives |